Previous 10 | Next 10 |
Anika Therapeutics, Inc. (ANIK) Q3 2022 Results Conference Call November 08, 2022 05:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations, ESG and Corporate Communications Dr. Cheryl Blanchard - President and Chief Executive Officer Mi...
Anika Therapeutics press release ( NASDAQ: ANIK ): Q3 Non-GAAP EPS of -$0.05 beats by $0.18 . Revenue of $40.3M (+1.9% Y/Y) beats by $2.71M . For further details see: Anika Therapeutics Non-GAAP EPS of -$0.05 beats by $0.18, revenue of $40.3M beats by $2....
Third Quarter Revenue Growth of 2% Third Phase III Clinical Trial for Cingal®, Next Generation Osteoarthritis Pain Product, Achieved Primary Endpoint Demonstrating Superiority Over Steroid Alone Pivotal Phase III Clinical Trial for Hyalofast®, HA-Based, Single-...
Study Demonstrated Superiority of Cingal, a Single-Injection Hyaluronic Acid-Based Viscosupplement Combined with Fast-Acting Steroid, Over Steroid Alone, for Osteoarthritis Pain Relief at 26 Weeks Study Builds on Prior Phase III Study Data that Demonstrated Superiority over Plac...
BEDFORD, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its third quarter 2022 financial results after the close of the market on Tue...
BEDFORD, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, today announced the limited market release and the first surgeries performed using the X-Twist Fixation System. Chr...
Anika Therapeutics, Inc. (ANIK) Q2 2022 Earnings Conference Call August 03, 2022, 05:00 PM ET Company Participants Mark Namaroff - Vice President, Investor Relations, ESG and Corporate Communications Cheryl Blanchard - President and Chief Executive Officer Michae...
The following slide deck was published by Anika Therapeutics, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Anika Therapeutics, Inc. 2022 Q2 - Results - Earnings Call Presentation
Anika Therapeutics press release ( NASDAQ: ANIK ): Q2 Non-GAAP EPS of -$0.12 beats by $0.09 . Revenue of $39.7M (+4.2% Y/Y) beats by $1.85M . The Company continues to expect its overall revenue for fiscal year 2022 to be toward the upper end of its guidance ran...
Second quarter revenue growth up 4% X-Twist ™ 510(k) clearance received; Limited market release on schedule for 2H 2022 BEDFORD, Mass., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in earl...
News, Short Squeeze, Breakout and More Instantly...
Anika Therapeutics Inc. Company Name:
ANIK Stock Symbol:
NASDAQ Market:
Anika Therapeutics Inc. Website:
BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early interven...
BEDFORD, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, today announced that the Company plans to issue its first quarter 2024 financial results after the close of the market on Wednesda...
2024-04-09 16:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...